Low-Tone Ho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Low-Tone Ho has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
Yung-Pei Hsu
Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
10 shared publicationsKuang-Chung Shih
Division of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
9 shared publicationsChi-Chang Juan
Institute of Physiology, National Yang-Ming University, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan
6 shared publicationsChing-Fai Kwok
Division of Endocrinology & Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC; National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC; Cheng Hsin General Hospital, Taipei, Taiwan, ROC
6 shared publicationsChii-Min Hwu
5 shared publicationsChing Fai Kwok
Division of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital and Cheng Hsin General Hospital., Taipei
5 shared publications
Latest Publications
- Open Access
- 18 October 2021
- Published by Springer Nature in Research Square
A Single Center, Open-Labeled Trial To Investigate The Pharmacokinetics of Insulin Detemir in Healthy Taiwanese Subjects
Backgrounds: Insulin detemir(nn304) is a long-acting insulin analogue reported to provide more predictable blood glucose level throughout the day, leading to a lower within-subject variability compared to NPH insulin. Pharmacokinetic profiles of insulin detemir had not been investigated in Taiwanese. This study was to determine whether there is a differencebetween Taiwanese subjects in pharmacokinetic profile of insulin detemir compared to Caucasian subjects.Methods: Pharmacokinetic profile of insulin detemir was measured in twenty male Taiwaneses(nn304-3023). Eligible subjects were given insulin detemir as a single dose subcutaneous injection at 0.5 U/kg body weight in the mid-thigh using NovoPen® 3 device. 32-hour serum insulin detemir concentrations were measured. Hypoglycemia and adverse events were recorded. The results were compared to data obtained from a previous trial inCaucasian subjects (nn304-1451).Results: There was no significant difference between Taiwanese (nn304-3023) and Caucasian(nn304-1451) in the primary endpoint, AUC(0–∝), and the secondary endpoints, AUC(0–24h), and t1/2. However, the secondary endpoints, Cmax was 40% higher, tmax was shorter(270.0 vs. 420.0 min) and AUC(0–5h) was 2-fold more in Taiwanese. When only male subjects were included in the comparator trial (nn304-1451), the t1/2 was significantly shorter in Taiwanese(348 min vs 404 min). There was no significant difference in the mean blood glucose concentrations between Taiwanese and Caucasian subjects. A single episode of hypoglycemia(53 mg/dL) was reported in a 24-year-old male approximately 2.5 hours after the administration of insulin detemir. He was able to treat himself for the episode.Conclusion: In this pharmacokinetic evaluation of a single dose administration of insulin detemir in Taiwanese male subjects, the AUC(0–∝), and AUC(0–24h) were not different from that of Caucasians in the comparator trial. However, insulin detemir appeared to be more rapidly absorbed in Taiwanese males. Further studies are warranted to elucidate its pharmacodynamic response and mechanisms. Finally, there was no clinically relevant safety concern raised in this study. (Funded by research grant from Novo Nordisk, Taiwan; first registration date 22/12/2011 ClinicalTrials.gov number, NCT01497587.
- 18 October 2021
- Published by Springer Nature in Research Square
Open AccessA Single Center, Open-Labeled Trial To Investigate The Pharmacokinetics of Insulin Detemir in Healthy Taiwanese Subjects
Backgrounds: Insulin detemir(nn304) is a long-acting insulin analogue reported to provide more predictable blood glucose level throughout the day, leading to a lower within-subject variability compared to NPH insulin. Pharmacokinetic profiles of insulin detemir had not been investigated in Taiwanese. This study was to determine whether there is a differencebetween Taiwanese subjects in pharmacokinetic profile of insulin detemir compared to Caucasian subjects.Methods: Pharmacokinetic profile of insulin detemir was measured in twenty male Taiwaneses(nn304-3023). Eligible subjects were given insulin detemir as a single dose subcutaneous injection at 0.5 U/kg body weight in the mid-thigh using NovoPen® 3 device. 32-hour serum insulin detemir concentrations were measured. Hypoglycemia and adverse events were recorded. The results were compared to data obtained from a previous trial inCaucasian subjects (nn304-1451).Results: There was no significant difference between Taiwanese (nn304-3023) and Caucasian(nn304-1451) in the primary endpoint, AUC(0–∝), and the secondary endpoints, AUC(0–24h), and t1/2. However, the secondary endpoints, Cmax was 40% higher, tmax was shorter(270.0 vs. 420.0 min) and AUC(0–5h) was 2-fold more in Taiwanese. When only male subjects were included in the comparator trial (nn304-1451), the t1/2 was significantly shorter in Taiwanese(348 min vs 404 min). There was no significant difference in the mean blood glucose concentrations between Taiwanese and Caucasian subjects. A single episode of hypoglycemia(53 mg/dL) was reported in a 24-year-old male approximately 2.5 hours after the administration of insulin detemir. He was able to treat himself for the episode.Conclusion: In this pharmacokinetic evaluation of a single dose administration of insulin detemir in Taiwanese male subjects, the AUC(0–∝), and AUC(0–24h) were not different from that of Caucasians in the comparator trial. However, insulin detemir appeared to be more rapidly absorbed in Taiwanese males. Further studies are warranted to elucidate its pharmacodynamic response and mechanisms. Finally, there was no clinically relevant safety concern raised in this study. (Funded by research grant from Novo Nordisk, Taiwan; first registration date 22/12/2011 ClinicalTrials.gov number, NCT01497587.
- Open Access
- 1 October 2018
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 81 (10) , 884-891
The Shipai cohort for cardiovascular metabolic risk factors and outcome study — Design and preliminary results
In 2009, a community-based cohort study was initiated in the Shipai area of the Shilin and Beitou districts in Taipei. Residents were randomly sampled by age (young adults: 35–44 years and middle-aged adults: 45–55 years) and urbanization (rural and urban). Residents who agreed to participate were scheduled to receive examinations (physical and blood) and answer questionnaires. A ten-year follow-up is anticipated. Metabolic syndrome (MetS) was defined based on the Adult Treatment Panel III guidelines, and individuals with only one or two of the five MetS components was identified for prevention target. Results: The response rate of the 9000 invited residents was 10.1%. After screening, 906 participants were enrolled. While 31.0% (281) had no MetS components, 29.1% (264) had only one, and 22.0% (199) had two. MetS with at least three components was diagnosed in 17.9% (162) of the cohort. Concerning gender difference, 25.4% of men and 13.2% of women had MetS (p < 0.001). The percentage of MetS was higher in middle-aged participants than in young adults (20.5% versus 13.4%, p = 0.008). Forty-six percent of participants had central obesity. After adjusting for gender, age, and urbanization, the central obesity odds ratio for MetS was 23.7, with a 95% confidence internal of 13.1–42.7. Conclusion: Our preliminary results revealed a high MetS percentage among young and middle-aged adults in Taiwan, with central obesity being a particularly urgent prevention target. The research design and operational protocol of this cohort study may stimulate more research in the future....
- 1 October 2018
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 81 (10) , 884-891
Open AccessThe Shipai cohort for cardiovascular metabolic risk factors and outcome study — Design and preliminary results
In 2009, a community-based cohort study was initiated in the Shipai area of the Shilin and Beitou districts in Taipei. Residents were randomly sampled by age (young adults: 35–44 years and middle-aged adults: 45–55 years) and urbanization (rural and urban). Residents who agreed to participate were scheduled to receive examinations (physical and blood) and answer questionnaires. A ten-year follow-up is anticipated. Metabolic syndrome (MetS) was defined based on the Adult Treatment Panel III guidelines, and individuals with only one or two of the five MetS components was identified for prevention target. Results: The response rate of the 9000 invited residents was 10.1%. After screening, 906 participants were enrolled. While 31.0% (281) had no MetS components, 29.1% (264) had only one, and 22.0% (199) had two. MetS with at least three components was diagnosed in 17.9% (162) of the cohort. Concerning gender difference, 25.4% of men and 13.2% of women had MetS (p < 0.001). The percentage of MetS was higher in middle-aged participants than in young adults (20.5% versus 13.4%, p = 0.008). Forty-six percent of participants had central obesity. After adjusting for gender, age, and urbanization, the central obesity odds ratio for MetS was 23.7, with a 95% confidence internal of 13.1–42.7. Conclusion: Our preliminary results revealed a high MetS percentage among young and middle-aged adults in Taiwan, with central obesity being a particularly urgent prevention target. The research design and operational protocol of this cohort study may stimulate more research in the future....
- 8 December 2016
- Published by Wiley in Proteomics
- Vol. 17 (1-2)
Using proteomics to discover novel biomarkers for fatty liver development and response to CB1R antagonist treatment in an obese mouse model
Over activity of cannabinoid receptor type 1 (CB1R) plays a key role in increasing the incidence of obesity‐induced non‐alcoholic fatty liver disease. Tissue proteome analysis has been applied to investigate the bioinformatics regarding the mode of action and therapeutic mechanism. The aim of this study was to explore the potential pathways altered with CB1R in obesity‐induced fatty liver. Male C57BL/6 mice were fed either a standard chow diet (STD) or a high‐fat diet (HFD) with or without 1‐week treatment of CB1R inverse agonist AM251 at 5 mg/kg. Then, liver tissues were harvested for 2DE analysis and protein profiles were identified by using MALDI‐MS. Results showed that eight of significantly altered protein spots at the level of changes > twofold were overlapped among the three groups, naming major urinary protein 1, ATP synthase subunit β, glucosamine‐fructose‐6‐phosphate aminotransferase 1, zine finger protein 2, s‐adenosylmethionine synthase isoform type‐1, isocitrate dehydrogenase subunit α, epoxide hydrolase 2 and 60S acidic ribosomal protein P0. These identified proteins were involved in glucose/lipid metabolic process, xenobiotic metabolic system, and ATP synthesized process in mitochondria. Based on the findings, we speculated that CB1R blockade might exert its anti‐metabolic disorder effect via improvement of mitochondrial function in hepatic steatosis in HFD condition.
- 8 December 2016
- Published by Wiley in Proteomics
- Vol. 17 (1-2)
Using proteomics to discover novel biomarkers for fatty liver development and response to CB1R antagonist treatment in an obese mouse model
Over activity of cannabinoid receptor type 1 (CB1R) plays a key role in increasing the incidence of obesity‐induced non‐alcoholic fatty liver disease. Tissue proteome analysis has been applied to investigate the bioinformatics regarding the mode of action and therapeutic mechanism. The aim of this study was to explore the potential pathways altered with CB1R in obesity‐induced fatty liver. Male C57BL/6 mice were fed either a standard chow diet (STD) or a high‐fat diet (HFD) with or without 1‐week treatment of CB1R inverse agonist AM251 at 5 mg/kg. Then, liver tissues were harvested for 2DE analysis and protein profiles were identified by using MALDI‐MS. Results showed that eight of significantly altered protein spots at the level of changes > twofold were overlapped among the three groups, naming major urinary protein 1, ATP synthase subunit β, glucosamine‐fructose‐6‐phosphate aminotransferase 1, zine finger protein 2, s‐adenosylmethionine synthase isoform type‐1, isocitrate dehydrogenase subunit α, epoxide hydrolase 2 and 60S acidic ribosomal protein P0. These identified proteins were involved in glucose/lipid metabolic process, xenobiotic metabolic system, and ATP synthesized process in mitochondria. Based on the findings, we speculated that CB1R blockade might exert its anti‐metabolic disorder effect via improvement of mitochondrial function in hepatic steatosis in HFD condition.
- 29 January 2016
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 37 (3) , 743-754
Cannabinoid receptor type 1 mediates high-fat diet-induced insulin resistance by increasing forkhead box O1 activity in a mouse model of obesity
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- 29 January 2016
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 37 (3) , 743-754
Cannabinoid receptor type 1 mediates high-fat diet-induced insulin resistance by increasing forkhead box O1 activity in a mouse model of obesity
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications
- 1 May 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 460 (4) , 1063-1068
Major urinary protein 1 interacts with cannabinoid receptor type 1 in fatty acid-induced hepatic insulin resistance in a mouse hepatocyte model
- 1 May 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 460 (4) , 1063-1068
Major urinary protein 1 interacts with cannabinoid receptor type 1 in fatty acid-induced hepatic insulin resistance in a mouse hepatocyte model
- 1 May 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 460 (3) , 497-503
Endothelin-1 exacerbates development of hypertension and atherosclerosis in modest insulin resistant syndrome
- 1 May 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 460 (3) , 497-503
Endothelin-1 exacerbates development of hypertension and atherosclerosis in modest insulin resistant syndrome
- 1 August 2014
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 451 (2) , 263-269
Angiotensin II enhances endothelin-1-induced vasoconstriction through upregulating endothelin type A receptor
- 1 August 2014
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 451 (2) , 263-269
Angiotensin II enhances endothelin-1-induced vasoconstriction through upregulating endothelin type A receptor
- Open Access
- 5 May 2014
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 5 (6) , 637-638
Look Action for Health in Diabetes trial: What we have learned in terms of real world practice and clinical trials
- 5 May 2014
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 5 (6) , 637-638
Open AccessLook Action for Health in Diabetes trial: What we have learned in terms of real world practice and clinical trials
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 4, 68631
Endothelin Type A Receptor Genotype is a Determinant of Quantitative Traits of Metabolic Syndrome in Asian Hypertensive Families: A SAPPHIRe Study
Co-heritability of hypertension and insulin resistance (IR) within families not only implies genetic susceptibility may be responsible for these complex traits but also suggests a rational that biological candidate genes for hypertension may serve as markers for features of the metabolic syndrome (MetS). Thus we determined whether the T323C polymorphism (rs5333) of endothelin type A (ETA) receptor, a predominant receptor evoking potent vasoconstrictive action of endothelin-1, contributes to susceptibility to IR-associated hypertension in 1694 subjects of Chinese and Japanese origins. Blood pressures (BPs) and biochemistries were measured. Fasting insulin level, insulin-resistance homeostasis model assessment (HOMAIR) score, and area under curve of insulin concentration (AUCINS) were selected for assessing insulin sensitivity. Genotypes were obtained by methods of polymerase chain reaction-restriction fragment length polymorphism. Foremost findings were that minor allele frequency of the T323C polymorphism was noticeable lower in our overall Asian subjects compared to multi-national population reported in gene database; moreover both the genotypic and allelic frequencies of the polymorphism were significantly different between the two ethnic groups we studied. The genotype distributions at TT/TC/CC were 65, 31, 4% in Chinese and 51, 41, 8% in Japanese, respectively (p < 0.0001). Additionally, carriers of the C homozygote revealed characteristics of IR, namely significantly higher levels of fasting insulin, HOMAIR score, and AUCINS at 29.3, 35.3, and 39.3%, respectively, when compared to their counterparts with TT/TC genotypes in Chinese. Meanwhile, the CC genotype was associated with a higher level of high density lipoprotein cholesterol in Japanese. No association of the polymorphism with BP was observed. This study demonstrated for the first time that T323C polymorphism of ETA receptor gene was associated with an adverse insulin response in Chinese and a favorite atherogenic index in Japanese.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 4, 68631
Open AccessEndothelin Type A Receptor Genotype is a Determinant of Quantitative Traits of Metabolic Syndrome in Asian Hypertensive Families: A SAPPHIRe Study
Co-heritability of hypertension and insulin resistance (IR) within families not only implies genetic susceptibility may be responsible for these complex traits but also suggests a rational that biological candidate genes for hypertension may serve as markers for features of the metabolic syndrome (MetS). Thus we determined whether the T323C polymorphism (rs5333) of endothelin type A (ETA) receptor, a predominant receptor evoking potent vasoconstrictive action of endothelin-1, contributes to susceptibility to IR-associated hypertension in 1694 subjects of Chinese and Japanese origins. Blood pressures (BPs) and biochemistries were measured. Fasting insulin level, insulin-resistance homeostasis model assessment (HOMAIR) score, and area under curve of insulin concentration (AUCINS) were selected for assessing insulin sensitivity. Genotypes were obtained by methods of polymerase chain reaction-restriction fragment length polymorphism. Foremost findings were that minor allele frequency of the T323C polymorphism was noticeable lower in our overall Asian subjects compared to multi-national population reported in gene database; moreover both the genotypic and allelic frequencies of the polymorphism were significantly different between the two ethnic groups we studied. The genotype distributions at TT/TC/CC were 65, 31, 4% in Chinese and 51, 41, 8% in Japanese, respectively (p < 0.0001). Additionally, carriers of the C homozygote revealed characteristics of IR, namely significantly higher levels of fasting insulin, HOMAIR score, and AUCINS at 29.3, 35.3, and 39.3%, respectively, when compared to their counterparts with TT/TC genotypes in Chinese. Meanwhile, the CC genotype was associated with a higher level of high density lipoprotein cholesterol in Japanese. No association of the polymorphism with BP was observed. This study demonstrated for the first time that T323C polymorphism of ETA receptor gene was associated with an adverse insulin response in Chinese and a favorite atherogenic index in Japanese.
- Open Access
- 29 July 2012
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 12 (1) , 58
Common ALDH2 genetic variants predict development of hypertension in the SAPPHIRe prospective cohort: Gene-environmental interaction with alcohol consumption
Background: Genetic variants near/within the ALDH2 gene encoding the mitochondrial aldehyde dehydrogenase 2 have been associated with blood pressure and hypertension in several case–control association studies in East Asian populations. Methods: Three common tag single nucleotide polymorphisms (tagSNP) in the ALDH2 gene were genotyped in 1,134 subjects of Chinese origin from the Stanford Asia-Pacific Program for Hypertension and Insulin Resistance (SAPPHIRe) family cohort. We examined whether the ALDH2 SNP genotypes predicted the development of hypertension in the prospective SAPPHIRe cohort. Results: Over an average follow-up period of 5.7 years, carriers homozygous for the rs2238152 T allele in the ALDH2 gene were more likely to progress to hypertension than were non-carriers (hazard ratio [HR], 2.88, 95% confidence interval [CI], 1.06-7.84, P = 0.03), corresponding to a population attributable risk of ~7.1%. The risk associated with the rs2238152 T allele were strongest in heavy/moderate alcohol drinkers and was reduced in non-drinkers, indicating an interaction between ALDH2 genetic variants and alcohol intake on the risk of hypertension (P for interaction = 0.04). The risk allele was associated with significantly lower ALDH2 gene expression levels in human adipose tissue. Conclusion: ALDH2 genetic variants were associated with progression to hypertension in a prospective Chinese cohort. The association was modified by alcohol consumption.
- 29 July 2012
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 12 (1) , 58
Open AccessCommon ALDH2 genetic variants predict development of hypertension in the SAPPHIRe prospective cohort: Gene-environmental interaction with alcohol consumption
Background: Genetic variants near/within the ALDH2 gene encoding the mitochondrial aldehyde dehydrogenase 2 have been associated with blood pressure and hypertension in several case–control association studies in East Asian populations. Methods: Three common tag single nucleotide polymorphisms (tagSNP) in the ALDH2 gene were genotyped in 1,134 subjects of Chinese origin from the Stanford Asia-Pacific Program for Hypertension and Insulin Resistance (SAPPHIRe) family cohort. We examined whether the ALDH2 SNP genotypes predicted the development of hypertension in the prospective SAPPHIRe cohort. Results: Over an average follow-up period of 5.7 years, carriers homozygous for the rs2238152 T allele in the ALDH2 gene were more likely to progress to hypertension than were non-carriers (hazard ratio [HR], 2.88, 95% confidence interval [CI], 1.06-7.84, P = 0.03), corresponding to a population attributable risk of ~7.1%. The risk associated with the rs2238152 T allele were strongest in heavy/moderate alcohol drinkers and was reduced in non-drinkers, indicating an interaction between ALDH2 genetic variants and alcohol intake on the risk of hypertension (P for interaction = 0.04). The risk allele was associated with significantly lower ALDH2 gene expression levels in human adipose tissue. Conclusion: ALDH2 genetic variants were associated with progression to hypertension in a prospective Chinese cohort. The association was modified by alcohol consumption.